Download PDF
Arthritis und Rheuma 2019; 39(06): 409-413
DOI: 10.1055/a-0992-3080
Kinderrheumatologie | Übersichtsartikel
© Georg Thieme Verlag KG Stuttgart · New York

Therapie der kindlichen Uveitis intermedia und posterior mit intravitrealen Steroiden

Intravitreal steroids for the treatment of paediatric intermediate or posterior uveitis
Sibylle Winterhalter
1   Universitäts Augenklinik, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health
› Author Affiliations
Further Information

Publication History

Publication Date:
18 December 2019 (online)

Also available at
   Permissions and Reprints

ZUSAMMENFASSUNG

Die Uveitis im Kindesalter weist ein hohes Erblindungsrisiko auf. Bei einer nicht infektiösen Uveitis intermedia und posterior sind lokal applizierte Steroid-Augentropfen nicht ausreichend wirksam, sodass bei Visusverschlechterung und Komplikationen eine systemische Therapie erfolgen muss. Diese entspricht im Wesentlichen dem Therapiealgorithmus der JIA-Assoziierten Uveitis anterior wie in der S2k-Leitlinie 045–012 zur Diagnostik und antientzündlichen Therapie der Uveitis bei juveniler idiopathischer Arthritis mit Stand 01/2018 beschrieben. Bei pädiatrischen Patienten jedoch, die nur an einem Auge ohne Systemerkrankung leiden, wäre eine intravitreale Therapie wünschenswert, um Nebenwirkungen einer systemischen Therapie zu vermeiden. Intravitreal verabreichte Steroide weisen zwar eine sehr gute Wirksamkeit auf. Leider besteht jedoch das Risiko für ein Steroid-induziertes Glaukom sowie eine Steroid-induzierte Katarakt, sodass intravitreal verabreichte Steroide laut S2k-Leitlinie nur als Rescue-Therapie genutzt werden sollten.

ABSTRACT

Uveitis in childhood carries a high risk for vision-threatening complications. In non infectious intermediate and posterior uveitis topical steroids are usually not effective enough and systemic treatment may be necessary in cases of visual deterioration and complications. In these cases systemic therapy follows the therapy algorithm of the S2k-guidelines 045–012 for the diagnosis and anti inflammatory therapy of uveitis in juvenile idiopathic arthritis 01/2018. In paediatric patients with only one eye involvement without systemic disease, an intravitreal therapy would be preferable to avoid systemic side effects. An intravitreal steroid application is highly effective, but carries a risk for steroid induced glaucoma and steroid induced cataract. Therefore the S2k-guidelines only recommend intravitreal steroid application as a rescue therapy.

Schlüsselwörter

Uveitis intermedia - Uveitis posterior - intravitreale Steroide - Dexamethasonimplantate

Keywords

Intermediate uveitis - posterior uveitis - intravitreal steroids - dexamethasone implants
 

  • Literatur

  • 1 Jabs DA, Nussenblatt RB, Rosenbaum JT. et al. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005; 140 (03) 509-516
    CrossrefPubMedGoogle Scholar
  • 2 Heiligenhaus A, Niewerth M, Mingels A. et al. Epidemiology of uveitis in juvenile idiopathic arthritis from a national paediatric rheumatologic and opthalmologic database. KlinMonblAugenheilkd 2005; 222 (12) 993-1001
    Google Scholar
  • 3 Pleyer U, Sengler C. Intraokulare Entzündung im Kindesalter. Diagnostik und Differentialdiagnostik. Klin Monatsbl Augenheilkd 2006; 223: R85-R101
    Article in Thieme ConnectGoogle Scholar
  • 4 Mackensen F, Baydoun L, Garweg J. et al. Intermediate uveitis: guidelines of the German Ophthalmological Society and the Professional Association of German Ophthalmologists. Ophthalmologe 2014; 111 (11) 1033-1040
    CrossrefPubMedGoogle Scholar
  • 5 Engelmann K, Neß T, Greiner K. et al. Uveitis intermedia im Kindesalter. Klin Monatsbl Augenheilkd 2007; 224: 462-468
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Nussenblatt RB, Palestine AG, Chan CC. et al. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 1985; 92 (04) 467-471
    CrossrefPubMedGoogle Scholar
  • 7 Davis JL, Madow B, Cornett J. et al. Scale for Photographic Grading of Vitreous Haze in Uveitis. Am J Ophthalmol 2010; 150 (05) 637-41.e1
    CrossrefPubMedGoogle Scholar
  • 8 Biswas J, Sudharshan S. Intermediate Uveitis. In Gupta A, Gupta A, Herbort CP. et al, eds Uveitis text and imaging. 01. Neu Dehli, Indien: jaypeebrothers; 2009: 348-362
    Google Scholar
  • 9 Heiligenhaus A, Minden K, Föll D. et al. Uveitis in juvenile idiopathic arthritis. Dtsch Arztebl Int 2015; 112 (06) 92-100
    PubMedGoogle Scholar
  • 10 Lowder C, Belfort Jr R, Lightman S. et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011; 129 (05) 545-553
    CrossrefPubMedGoogle Scholar
  • 11 Chang-Lin JE, Attar M, Archeampong AA. et al. Pharmacokinetics and pharmocodynamics of a sustained- release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 2011; 5 52 (01) 80-86
    Google Scholar
  • 12 Pohlmann D, vom Brocke GA, Winterhalter S. et al. Dexamethasone inserts in Noninfectious uveitis: A single center experience. Ophthalmology 2018; 125 (07) 1088-1099
    CrossrefPubMedGoogle Scholar
  • 13 Bratton ML, He YG, Weakley DR. Dexamethasone intravitreal implant (Ozurdex) for the treatment of pediatric uveitis. J AAPOS 2014; 18 (02) 110-113
    CrossrefPubMedGoogle Scholar
  • 14 Sella R, Oray M, Friling R. et al. Dexamethasone intravitreal implant (Ozurdex® for pediatric uveitis. Graefes Arch Clin Exp Ophthalmol 2015; 253 (10) 1777-1782
    CrossrefPubMedGoogle Scholar
  • 15 Lei S, Lam WC. Efficacy and safety of dexamethasone intravitreal implant for refractory macular edema in children. Can J Ophthalmol 2015; 50 (03) 236-241
    CrossrefPubMedGoogle Scholar
  • 16 Tomkins-Netzer O, Talat L, Seguin-Greenstein S. et al. Outcome of Treating Pediatric Uveitis With Dexamethasone Implants. Am J Ophthalmol 2016; 161: 110-115
    CrossrefPubMedGoogle Scholar
  • 17 Taylor SR, Tomkins-Netzer O, Joshi L. et al. Dexamethasone implant in pediatric uveitis. Ophthalmology 2012; 119 (11) 2412
    CrossrefPubMedGoogle Scholar
  • 18 Winterhalter S, Behrens UD, Salchow D. et al. Dexamethasone implants in paediatric patients with noninfectious intermediate or posterior uveitis: first prospective exploratory case series. BMC Ophthalmol 2017; 17 (01) 252
    CrossrefPubMedGoogle Scholar
  • 19 Burkholder BM, Moradi A, Thorne JE. et al. The Dexamethasone Intravitreal Implant for Noninfectious Uveitis: Practice Patterns Among Uveitis Specialists. Ocul Immunol Inflamm 2015; 23 (06) 444-453
    CrossrefPubMedGoogle Scholar
  • 20 Becker B. Intraocular pressure response to topical corticosteroids. Invest Ophthalmol 1965; 4: 198-205
    PubMedGoogle Scholar
  • 21 Pichi F, Nucci P, Baynes K. et al. Sustained-release dexamethasone intravitreal implant in juvenile idiopathic arthritis-related uveitis. Int Ophthalmol 2017; 37 (01) 221-228
    CrossrefPubMedGoogle Scholar
  • 22 Arcinue CA, Cerón OM, Foster CS. A Comparison Between the Fluocinolone Acetonide (Retisert) and Dexamethasone (Ozurdex) Intravitreal Implants in Uveitis. J Ocular Pharmacology and Therapeutics 2013; 29 (05) 501-507
    PubMedGoogle Scholar
  • 23 De Smet MD. Corticoseroid Intravitreal Implants. Dev Ophthalmol 2012; 51: 122-133
    PubMedGoogle Scholar
  • 24 Kiddee W, Trope GE, Sheng L. et al. Intraocular Pressure Monitoring Post Intravitreal Steroids: A Systematic Review. Surv Ophthalmol 2013; 58 (04) 291-310
    CrossrefPubMedGoogle Scholar
  • 25 Jones R 3rd, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol 2006; 17 (02) 163-167
    PubMedGoogle Scholar
  • 26 Nuyen B, Weinreb RN, Robbins SL. Steroid- induced glaucoma in the pediatric population. J AAPOS 2017; 21: 1-6
    CrossrefPubMedGoogle Scholar
  • 27 Kwok AKH, Lam DSC, Ng JSK. et al. Ocular-hypertensive Response to Topical Steroids in Children. Ophthalmology 1996; 104 (12) 2112-2116
    Google Scholar
  • 28 Jaafar MS, Kazi GA. Normal intraocular pressure in children: a comparative study of the Perkins applanation tonometer and the pneumatonometer. J Pediatr Ophthalmol Strabismus 1993; 30: 284-287
    PubMedGoogle Scholar
  • 29 Winterhalter S, Ruokonen P, van der Velden KH. et al. Intravitreal implants: drug carriers and carriers of hope?. Ophthalmologe 2011; 108 (03) 222-229
    CrossrefPubMedGoogle Scholar
  • 30 Patel CC, Mandava N, Oliver SC. et al. Treatment of intractable posterior uveitis in pediatric patients with the fluocinolone acetonide intravitreal implant (Retisert). Retina 2012; 32 (03) 537-542
    CrossrefPubMedGoogle Scholar
  • 31 Sallam A, Comer RM, Chang JH. et al. Short-term safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema in children. Arch Ophthlmol 2008; 126 (02) 200-205
    Google Scholar